Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Vir Biotechnology (NASDAQ:VIR) and raises the price target from $15 to $19.
June 05, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has maintained a Buy rating on Vir Biotechnology and increased the price target from $15 to $19.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100